ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1285

The Impact of Race and Social Determinants of Health on Patient Reported Outcomes in Pediatric Lupus: A CARRA Registry Study

William Soulsby1, Rebecca Olveda2, Jie He3, Laura Berbert4, Edie Weller3, Kamil Barbour5, Kurt Greenlund5, Laura Schanberg6, Emily Von Scheven1, Aimee Hersh7, Mary Beth Son8, Joyce Chang8 and Andrea Knight9, and the CARRA Registry Investigators, 1University of California, San Francisco, San Francisco, CA, 2Palo Alto Medical Foundation, Dublin, CA, 3Boston Children's Hospital, Boston, MA, 4Boston Children's Hospital, Belmont, MA, 5CDC, Alpharetta, GA, 6Duke University Medical Center, DURHAM, NC, 7University of Utah, Salt Lake City, UT, 8Boston Children's Hospital, Brookline, MA, 9Division of Rheumatology, The Hospital for Sick Children; Neurosciences and Mental Health, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada

Meeting: ACR Convergence 2024

Keywords: Disparities, Patient reported outcomes, Pediatric rheumatology, race/ethnicity, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: Pediatric Rheumatology – Clinical Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Minoritized race and social determinants of health (SDoH) are associated with lower achievement of the low lupus disease activity state (LLDAS) and higher cumulative prednisone exposure among children with pediatric lupus (pSLE). It is not known if race and SDoH are associated with patient-reported outcomes (PROs). Therefore, we sought to determine how race and SDoH associate with PROs among a cohort with pSLE in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry. We hypothesized that functional disability and worse overall health would be observed among those of minoritized race.  

Methods: This cohort study included children with pSLE enrolled in the CARRA Registry during March 2017—December 2021 with baseline and at least one follow-up visit and a valid U.S. ZIP code. The primary exposure was self-identified race or ethnicity. SDoH of interest were insurance status and area deprivation index (ADI). The primary outcomes were 1) any level of functional disability (as defined by a Child Health Assessment Questionnaire [CHAQ] score >0) and 2) overall health (as measured by the PROMIS Global Health-7, with higher scores indicating better health). Associations between race and/or ethnicity and the outcomes were examined using univariate and multivariable linear or logistic regression models, adjusted for covariates (insurance status, ADI, age at enrollment, sex, major organ involvement, medication use, disease duration at enrollment, and secondary rheumatologic disease). A subject-level random effect was included in the PROMIS model to account for repeated measures.  Differences in collection of PROs by race and ADI were analyzed by chi-squared testing.

Results: 540 children with pSLE self-identified as 27% Black, 25% White, 23% Latino/a, 11% Asian, 9% more than one race, and 5% Other. Most had CHAQ (86%) and PROMIS Global Health-7 (74%) scores collected. Patient-reported functional disability was common (45.6%) and overall health (median T-score 35.6, IQR 32.4-40.4) was below average (median score T score of 38.8, IQR 34.0-42.1). In both unadjusted and adjusted analyses, neither race, living areas in the highest quartile for ADI, nor insurance status were statistically significantly associated with either outcome (Table 2). There were statistically significant racial differences between those with versus without collected PROMIS measures (p< 0.001, Table 3).   

Conclusion: PROs were below average for children with pSLE in the CARRA Registry with nearly half the cohort reporting functional disability and low overall health scores.  Race was not a statistically significant predictor of PROs that measure functional disability or overall health, in contrast to our prior work showing racial differences in clinical outcomes, including LLDAS achievement.  However, there were statistically significant differences for the collection of PROMIS scores between racial groups, which suggests bias affecting our estimates. Interventions to improve the completeness of data collection among those of minoritized race will be important to future study of racial disparities in pSLE using Registry data.

Supporting image 1

Table 1: Demographic features and patient-reported outcomes of children with cSLE in the CARRA Registry (between March 2017 and December 2021)

Supporting image 2

Logistic regression models to estimate the association between social determinants of health and disease features with functional disability (defined as a baseline Child Health Assessment Questionnaire [CHAQ] score of 0) and overall health (by PROMIS Global Health 7 scores throughout follow up) in children with cSLE in the CARRA Registry

Supporting image 3

Table 3: Differences in self-reported race or ethnicity and area deprivation index quartile between those with collected PROs versus those without collected PROs by chi-squared testing.


Disclosures: W. Soulsby: None; R. Olveda: None; J. He: None; L. Berbert: None; E. Weller: None; K. Barbour: None; K. Greenlund: None; L. Schanberg: Bristol-Myers Squibb(BMS), 5, Sanofi, 12, DSMB member, UCB, 12, DSMB Chair; E. Von Scheven: None; A. Hersh: None; M. Son: None; J. Chang: Century Therapeutics, 2; A. Knight: Pfizer, 6.

To cite this abstract in AMA style:

Soulsby W, Olveda R, He J, Berbert L, Weller E, Barbour K, Greenlund K, Schanberg L, Von Scheven E, Hersh A, Son M, Chang J, Knight A. The Impact of Race and Social Determinants of Health on Patient Reported Outcomes in Pediatric Lupus: A CARRA Registry Study [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/the-impact-of-race-and-social-determinants-of-health-on-patient-reported-outcomes-in-pediatric-lupus-a-carra-registry-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-impact-of-race-and-social-determinants-of-health-on-patient-reported-outcomes-in-pediatric-lupus-a-carra-registry-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology